Low risk myelodysplastic syndromes with del5q

Abstract

Del5q syndrome is myelodysplastic syndrome with well-known clinical manifestation of disease in the form of macrocytic anemia, which can be commonly accompanied by thrombocythemia. The disease is more common in women and is characterized by a relatively low percentage of transformation in acute myeloid leukemia. Currently the treatment of choice in this group of patients is lenalidomide, which allows to achieve higher rate of transfusion independence and cytogenetic responses.